[CD43 in B-cell chronic lymphocytic leukemia].

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• CD43, a cell membrane mucin, is found on activated B cells and CD5-positive B cells, which are implicated in B-cell chronic lymphocytic leukemia (B-CLL).
• While anti-CD43 antibodies are used in lymphoma diagnostics, CD43 expression on peripheral blood B cells in B-CLL patients is understudied.

Purpose of the Study:

• To evaluate CD43 expression on B-CLL cells.
• To compare CD43 expression with established B-CLL markers, CD5 and CD6.
• To investigate the relationship between CD43 expression and tumor burden.

Main Methods:

• Flow cytometry and two-color staining were used to analyze peripheral blood and bone marrow lymphocytes from 26 untreated B-CLL patients.
• Patients were stratified into two groups based on tumor mass score (TTM): Group I (TTM ≤ 9) and Group II (TTM > 9).

Main Results:

• The percentage of CD43+/CD19+ cells was higher in Group II (75%) compared to Group I (62.6%) (p < 0.05).
• Percentages of CD5+/CD19+ and CD6+/CD19+ cells significantly increased with disease progression (p < 0.002 and p < 0.03, respectively).
• CD43 expression showed a tendency to decrease with increasing tumor mass, while CD5 and CD6 expression increased.

Conclusions:

• CD43 is present on peripheral blood B-CLL cells and its expression increases with disease progression, albeit less pronouncedly than CD5 and CD6.
• CD43 expression appears independent of CD5 and CD6 and may decrease with tumor mass increase, potentially due to exocellular domain release.
• CD43+ B-CLL cells tend to accumulate in tissues, as indicated by higher percentages in bone marrow compared to peripheral blood.